142 related articles for article (PubMed ID: 17940497)
1. [Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis].
Vinagre F; Santos MJ; Silva JC
Acta Reumatol Port; 2007; 32(3):271-3. PubMed ID: 17940497
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
4. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
Jois RN; Leeder J; Gibb A; Gaffney K; Macgregor A; Somerville M; Scott DG
Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
[TBL] [Abstract][Full Text] [Related]
6. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
[TBL] [Abstract][Full Text] [Related]
7. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
Cheung PP; Tymms KE; Wilson BJ; Shadbolt B; Brook AS; Dorai Raj AK; Khoo KB
Intern Med J; 2008 Jun; 38(6):396-401. PubMed ID: 18336538
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study.
Collantes-Estevez E; Muñoz-Villanueva MC; Zarco P; Torre-Alonso JC; Gratacós J; González C; Sanmartí R; Cañete JD;
Rheumatology (Oxford); 2005 Dec; 44(12):1555-8. PubMed ID: 16118228
[TBL] [Abstract][Full Text] [Related]
9. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.
Jauregui E; Conner-Spady B; Russell AS; Maksymowych WP
J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645
[TBL] [Abstract][Full Text] [Related]
10. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up.
Gossec L; Le Henanff A; Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Alexandre C; Dougados M
Rheumatology (Oxford); 2006 Jul; 45(7):859-62. PubMed ID: 16436489
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment in ankylosing spondylitis: an observational study.
Nikas SN; Alamanos Y; Voulgari PV; Pliakou XI; Papadopoulos CG; Drosos AA
Ann Rheum Dis; 2005 Jun; 64(6):940-2. PubMed ID: 15564309
[TBL] [Abstract][Full Text] [Related]
12. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
13. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
[TBL] [Abstract][Full Text] [Related]
14. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup.
Keeling S; Oswald A; Russell AS; Maksymowych WP
J Rheumatol; 2006 Mar; 33(3):558-61. PubMed ID: 16463437
[TBL] [Abstract][Full Text] [Related]
15. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Baraliakos X; Listing J; Brandt J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Rudwaleit M; Sieper J; Braun J
Arthritis Res Ther; 2005; 7(3):R439-44. PubMed ID: 15899030
[TBL] [Abstract][Full Text] [Related]
16. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
van der Heijde D; Han C; DeVlam K; Burmester G; van den Bosch F; Williamson P; Bala M; Han J; Braun J
Arthritis Rheum; 2006 Aug; 55(4):569-74. PubMed ID: 16874778
[TBL] [Abstract][Full Text] [Related]
17. [The efficacy and safety of infliximab in patients with ankylosing spondylitis: results of an open-labeled multicenter study].
Bunchuk NV; Rumiantseva OA; Loginova EIu; Bochkova AG; Storozhakov GI; Ettinger OA; Kosiura SD; Kamalova RG; Valishina LM
Ter Arkh; 2010; 82(10):41-6. PubMed ID: 21341463
[TBL] [Abstract][Full Text] [Related]
18. [Intravenous high dose glucocorticoids in patients with ankylosing spondylitis].
Rumiantseva OA; Bochkova AG; Liginova EIu; Kiseleva NM; Pushkova OV; Bunchuk NV
Ter Arkh; 2006; 78(12):71-5. PubMed ID: 17294868
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
Baraliakos X; Listing J; Rudwaleit M; Brandt J; Alten R; Burmester G; Gromnica-Ihle E; Haibel H; Schewe S; Schneider M; Sörensen H; Zeidler H; Visvanathan S; Sieper J; Braun J
J Rheumatol; 2007 Mar; 34(3):510-5. PubMed ID: 17299842
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
Visvanathan S; Wagner C; Marini JC; Baker D; Gathany T; Han J; van der Heijde D; Braun J
Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
